Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) shot up 7.3% during mid-day trading on Wednesday . The company traded as high as C$0.30 and last traded at C$0.30. 107,500 shares traded hands during trading, a decline of 84% from the average session volume of 657,849 shares. The stock had previously closed at C$0.28.
Hemostemix Stock Performance
The stock has a market cap of C$32.67 million, a price-to-earnings ratio of -18.75 and a beta of 0.20. The business’s 50 day moving average is C$0.12 and its 200-day moving average is C$0.09.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Recommended Stories
- Five stocks we like better than Hemostemix
- How to Use the MarketBeat Stock Screener
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- Where to Find Earnings Call Transcripts
- 3 Buy-and-Hold Stocks for Long-Term Growth
- The Most Important Warren Buffett Stock for Investors: His Own
- Despite Short-Term Risks Freeport McMoran Worth a Look
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.